Adipokines and etiopathology of metabolic disorders

Saudi Medical Journal

Volumn 30, Issue 9, 2009, Pages 1123-1132

  Al Dokhi, Laila M ^a  

^a KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RECOMBINANT LEPTIN; RESISTIN;

ATHEROSCLEROSIS; DIABETES MELLITUS; DIET THERAPY; DRUG ACTIVITY; ENDOTHELIAL DYSFUNCTION; EXERCISE; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; METABOLIC DISORDER; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; REVIEW; WEIGHT REDUCTION;

ADIPOKINES; ANIMALS; HUMANS; METABOLIC DISEASES;

EID: 70449729465     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Jazet IM, Pijl H, Meinders AE. Adipose tissue as an endocrine organ: impact on insulin resistance. Neth J Med 2003; 61: 194-212. (Pubitemid 39089399)
2. Ahima RS, Saper CB, Flier JS, Elmquist JK. Leptin regulation of neuroendocrine systems. Front Neuroendocrinol 2000; 21: 263-307.
3. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808. (Pubitemid 38063703)
4. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-1830. (Pubitemid 38063705)
5. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772-783. (Pubitemid 44453463)
6. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001; 60: 329-339. (Pubitemid 32772448)
7. Ahima RS. Adipose tissue as an endocrine organ. Obesity (Silver Spring) 2006; 14 Suppl 5: 242S-249S.
8. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432. (Pubitemid 24365442)
9. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004; 116: 337-350
10. Ahima RS, Osei SY. Adipokines in obesity. Obesity and Metabolism 2008; 36: 182-197.
11. Lee GH, Proenca R, Montez JM, Carroll KM, Darvishzadeh JG, Lee JI, et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996; 379: 632-635. (Pubitemid 26053452)
12. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science. 1995; 269: 546-549.
13. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995; 269: 543-546.
14. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995; 269: 540-543.
15. Madej T, Boguski MS, Bryant SH. Threading analysis suggests that the obese gene product may be a helical cytokine. FEBS Lett 1995; 373: 13-18.
16. Zhang F, Basinski MB, Beals JM, Briggs SL, Churgay LM, Clawson DK, et al. Crystal structure of the obese protein leptin-E100. Nature 1997; 387: 206-209. (Pubitemid 27209439)
17. Frühbeck G, Jebb SA, Prentice AM. Leptin: physiology and pathophysiology. Clin Physiol 1998; 18: 399-419.
18. Grasso P, Leinung MC, Ingher SP, Lee DW. In vivo effects of leptin-related synthetic peptides on body weight and food intake in female ob/ob mice: localization of leptin activity to domains between amino acid residues 106-140. Endocrinology 1997; 138: 1413-1418. (Pubitemid 27137087)
19. Sinha MK, Sturis J, Ohannesian J, Magosin S, Stephens T, Heiman ML, et al. Ultradian oscillations of leptin secretion in humans. Biochemical and Biophysical Research Communications 1996; 228: 733-738. (Pubitemid 26421447)
20. Matkovic V, Ilich JZ, Badenhop NE, Skugor M, Clairmont A, Klisovic D, et al. Gain in body fat is inversely related to the nocturnal rise in serum leptin level in young females. J Clin Endocrinol Metab 1997; 82: 1368-13672. (Pubitemid 27200402)
21. Licinio J, Mantzoros C, Negrão AB, Cizza G, Wong ML, Bongiorno PB, et al. Human leptin levels are pulsatile and inversely related to pituitary-adrenal function. Nat Med. 1997; 3: 575-579. (Pubitemid 27198660)
22. Sinha MK, Opentanova I, Ohannesian JP, Kolaczynski JW, Heiman ML, Hale J, et al. Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting. J Clin Invest 1996; 98: 1277-1282. (Pubitemid 26322051)
23. Licinio J, Negrão AB, Mantzoros C, Kaklamani V, Wong ML, Bongiorno PB, et al. Sex differences in circulating human leptin pulse amplitude: clinical implications. J Clin Endocrinol Metab 1998; 83: 4140-4147. (Pubitemid 28513608)
24. Gat-Yablonski G, Phillip M. Leptin and regulation of linear growth. Curr Opin Clin Nutr Metab Care 2008; 11: 303-308.
25. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-295. (Pubitemid 26033933)
26. Münzberg H, Myers MG Jr. Molecular and anatomical determinants of central leptin resistance. Nat Neurosci 2005; 8: 566-570. (Pubitemid 40594195)
27. Howard JK, Cave BJ, Oksanen LJ, Tzameli I, Bjørbaek C, Flier JS. Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3. Nat Med 2004; 10: 734-738. (Pubitemid 38937639)
28. Mori H, Hanada R, Hanada T, Aki D, Mashima R, Nishinakamura H, et al. Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med 2004; 10: 739-743. (Pubitemid 38937640)
29. Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A, Haj F, Wang Y, Minokoshi Y, et al. PTP1B regulates leptin signal transduction in vivo. Dev Cell 2002; 2: 489-495. (Pubitemid 34436576)
30. Bence KK, Delibegovic M, Xue B, Gorgun CZ, Hotamisligil GS, Neel BG, et al. Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat Med 2006; 12: 917-924. (Pubitemid 44175143)
31. Leshan RL, Björnholm M, Münzberg H, Myers MG Jr. Leptin receptor signaling and action in the central nervous system. Obesity (Silver Spring) 2006; 14: 208S-212S
32. Banks WA, Kastin AJ, Huang W, Jaspan JB, Maness LM. Leptin enters the brain by a saturable system independent of insulin. Peptides 1996; 17: 305-311. (Pubitemid 26124406)
33. Banks WA, Niehoff ML, Martin D, Farrell CL. Leptin transport across the blood-brain barrier of the Koletsky rat is not mediated by a product of the leptin receptor gene. Brain Res 2002; 950: 130-136. (Pubitemid 35253924)
34. Banks WA, DiPalma CR, Farrell CL. Impaired transport of leptin across the blood-brain barrier in obesity. Peptides 1999; 20: 1341-2134
35. He W, Lam TK, Obici S, Rossetti L. Molecular disruption of hypothalamic nutrient sensing induces obesity. Nat Neurosci 2006; 9: 227-233 (Pubitemid 43164546)
36. Cota D, Proulx K, Smith KA, Kozma SC, Thomas G, Woods SC, et al. Hypothalamic mTOR signaling regulates food intake. Science 2006; 312: 927-930. (Pubitemid 43727328)
37. Grill HJ, Kaplan JM. The neuroanatomical axis for control of energy balance. Front Neuroendocrinol 2002; 23: 2-40.
38. Legradi G, Emerson CH, Ahima RS, Rand WM, Flier JS, Lechan RM. Arcuate nucleus ablation prevents fasting-induced suppression of ProTRH mRNA in the hypothalamic paraventricular nucleus. Neuroendocrinology 1998; 68: 89-97. (Pubitemid 28383252)
39. Cohen P, Zhao C, Cai X, Montez JM, Rohani SC, Feinstein P, et al. Selective deletion of leptin receptor in neurons leads to obesity. J Clin Invest 2001; 108: 1113-1121. (Pubitemid 32995369)
40. Morton GJ, Niswender KD, Rhodes CJ, Myers MG Jr, Blevins JE, Baskin DG, et al. Arcuate nucleus-specific leptin receptor gene therapy attenuates the obesity phenotype of Koletsky (fa(k)/fa(k)) rats. Endocrinology 2003; 144: 2016-2024.
41. Niswender KD, Baskin DG, Schwartz MW. Insulin and its evolving partnership with leptin in the hypothalamic control of energy homeostasis. Trends Endocrinol Metab 2004; 15: 362-369.
42. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1: 15-25. (Pubitemid 43960587)
43. Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 2004; 428: 569-574. (Pubitemid 38480541)
44. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Müller C, Carling D, et al. Leptin stimulates fatty acid oxidation by activating AMP-activated protein kinase. Nature 2002; 415: 339-343. (Pubitemid 34087557)
45. Cowley MA, Smart JL, Rubinstein M, Cerdán MG, Diano S, Horvath TL, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 2001; 411: 480-484. (Pubitemid 32494394)
46. Takahashi KA, Cone RD. Fasting induces a large, leptin-dependent increase in the intrinsic action potential frequency of orexigenic arcuate nucleus neuropeptide Y/Agouti-related protein neurons. Endocrinology 2005; 146: 1043-1047.
47. Spanswick D, Smith MA, Mirshamsi S, Routh VH, Ashford ML. Insulin activates ATP-sensitive K+ channels in hypothalamic neurons of lean, but not obese rats. Nat Neurosci 2000; 3: 757-758. (Pubitemid 30485698)
48. Howard JK, Lord GM, Matarese G, Vendetti S, Ghatei MA, Ritter MA, et al. Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice. J Clin Invest 1999; 104: 1051-1059. (Pubitemid 29536315)
49. Gat-Yablonski G, Phillip M. Leptin and regulation of linear growth. Curr Opin Clin Nutr Metab Care 2008; 11: 303-308.
50. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, et al. Role of leptin in the neuroendocrine response to fasting. Nature 1996; 382: 250-252. (Pubitemid 26251358)
51. Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110: 1093-1103. (Pubitemid 35215890)
52. Licinio J, Caglayan S, Ozata M, Yildiz BO, de Miranda PB, O'Kirwan F, et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci USA 2004; 101: 4531-4536. (Pubitemid 38437445)
53. Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 1999; 84: 3686-3695. Erratum in: J Clin Endocrinol Metab 2000; 85: 416. (Pubitemid 30645226)
54. McDuffie JR, Riggs PA, Calis KA, Freedman RJ, Oral EA, DePaoli AM, et al. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J Clin Endocrinol Metab 2004; 89: 4258-4263.
55. Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 2005; 54: 1994-2002. (Pubitemid 40911261)
56. Musso C, Cochran E, Javor E, Young J, Depaoli AM, Gorden P. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients. Metabolism 2005; 54: 255-263. (Pubitemid 40174856)
57. Liu L, Karkanias GB, Morales JC, Hawkins M, Barzilai N, Wang J, et al. Intracerebroventricular leptin regulates hepatic but not peripheral glucose fluxes. J Biol Chem 1998; 273: 31160-31167. (Pubitemid 28533128)
58. Gutiérrez-Juárez R, Obici S, Rossetti L. Melanocortin-independent effects of leptin on hepatic glucose fluxes. J Biol Chem 2004; 279: 49704-49715. (Pubitemid 39577774)
59. Légrádi G, Emerson CH, Ahima RS, Flier JS, Lechan RM. Leptin prevents fasting-induced suppression of prothyrotropin-releasing hormone messenger ribonucleic acid in neurons of the hypothalamic paraventricular nucleus. Endocrinology 1997; 138: 2569-2576. (Pubitemid 27215264)
60. Oosman SN, Lam AW, Harb G, Unniappan S, Lam NT, Webber T, et al. Treatment of obesity and diabetes in mice by transplant of gut cells engineered to produce leptin. Mol Ther 2008; 16: 1138-1145. (Pubitemid 351737080)
61. Al-Daghri NM, Al-Attas O, Al-Rubeaan K, Sallam R. Adipocytokine profile of type 2 diabetics in metabolic syndrome as defined by various criteria. Diabetes Metab Res Rev 2008; 24: 52-58. (Pubitemid 351176000)
62. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439-451.
63. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 2003; 278: 9073-9085. (Pubitemid 36800387)
64. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004; 279: 12152-12162. (Pubitemid 38445780)
65. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98: 2005-2010. (Pubitemid 32165613)
66. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-1295. (Pubitemid 35373562)
67. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7: 947-953. (Pubitemid 32756433)
68. Cortelazzi D, Corbetta S, Ronzoni S, Pelle F, Marconi A, Cozzi V, et al. Maternal and foetal resistin and adiponectin concentrations in normal and complicated pregnancies. Clin Endocrinol (Oxf) 2007; 66: 447-453. (Pubitemid 46239308)
69. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83
70. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002; 51: 2734-2741. (Pubitemid 34970926)
71. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476. (Pubitemid 30005109)
72. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599. (Pubitemid 30353893)
73. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360: 57-58. (Pubitemid 34756495)
74. Spranger J, Kroke A, Möhlig M, Bergmann MM, Ristow M, Boeing H, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226-228. (Pubitemid 36126226)
75. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-1737. (Pubitemid 38489895)
76. Nakamura Y, Shimada K, Fukuda D, Shimada Y, Ehara S, Hirose M, et al. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart 2004; 90: 528-533. (Pubitemid 38530170)
77. Spranger J, Verma S, Göhring I, Bobbert T, Seifert J, Sindler AL, et al. Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells. Diabetes 2006; 55: 141-1417. (Pubitemid 43343309)
78. Pan W, Tu H, Kastin AJ. Differential BBB interactions of three ingestive peptides: obestatin, ghrelin and adiponectin. Peptides 2006; 27: 911-916.
79. Fry M, Smith PM, Hoyda TD, Duncan M, Ahima RS, Sharkey KA, et al. Area postrema neurons are modulated by the adipocyte hormone adiponectin. J Neurosci 2006; 26: 9695-9702. (Pubitemid 44427708)
80. Nawrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, Trumbauer ME, et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2006; 281: 2654-2660. (Pubitemid 43845727)
81. Kubota N, Terauchi Y, Kubota T, Kumagai H, Itoh S, Satoh H, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and independent pathways. J Biol Chem 2006; 281: 8748-8755. (Pubitemid 43847980)
82. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, et al. Targeted disruption of AdipoR1 and AdipoR2 caused abrogation of adiponectin binding and metabolic actions. Nat Med 2007; 13: 332-339. (Pubitemid 46376688)
83. Schurgin S, Canavan B, Koutkia P, Depaoli A, Grinspoon S. Endocrine and metabolic effects of physiologic r-metHuLeptin administration during acute caloric deprivation in normal weight women. J Clin Endocrinol Metab 2004; 89: 5402-5409. (Pubitemid 39518416)
84. Yamauchi T, Kamon J, Minokoshi Y. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMPactivated protein kinase. Nat Med 2002; 8: 1288-1295. (Pubitemid 35373562)
85. Dekker J, Funahashi T, Nijpels G, Pilz S, Stehouwer C, Snijder M, et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J ClinEndocrinol Metab 2008; 93: 1489-1496.
86. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935. (Pubitemid 32472900)
87. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996; 271: 10697-10703. (Pubitemid 26145805)
88. Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol 2004; 219: 9-15. (Pubitemid 38638516)
89. Fisher FM, McTernan PG, Valsamakis G, Chetty R, Harte AL, Anwar AJ, et al. Differences in adiponectin protein expression: effect on fat depots and type 2 diabetic status. Horm Metab Res 2002; 34: 650-654. (Pubitemid 36398701)
90. Mather KJ, Funahashi T, Matsuzawa Y. Diabetes Prevention Program. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 2008; 57: 980-986.
91. Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB, et al. Adiponectin acts in the brain to decrease body weight. Nat Med 2004; 10: 524-529. (Pubitemid 38667912)
92. Housa D, Vernerova Z, Heracek J, Prochazka B, Cechak P, Kuncova J, et al. Adiponectin as a potential marker of prostate cancer progression: studies in organ-confined and locally advanced prostate cancer. Physiol Res 2008; 57: 451-458.
93. Steppan CM, Lazar MA. The current biology of resistin. J Intern Med 2004; 255: 439-447.
94. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003; 300: 472-476. (Pubitemid 38375833)
95. Yura S, Sagawa N, Itoh H, Kakui K, Nuamah MA, Korita D, et al. Resistin is expressed in the human placenta. J Clin Endocrinol Metab 2003; 88: 1394-1397.
96. Minn AH, Patterson NB, Pack S, Hoffmann SC, Gavrilova O, Vinson C, et al. Resistin is expressed in pancreatic islets. Biochem Biophys Res Commun 2003; 310: 641-645.
97. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50: 2199-2202. (Pubitemid 33641901)
98. Rangwala SM, Rich AS, Rhoades B, Shapiro JS, Obici S, Rossetti L, et al. Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 2004; 53: 1937-1941. (Pubitemid 38970738)
99. Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Qi Y, et al. Regulation of fasted blood glucose by resistin. Science 2004; 303: 1195-1198. (Pubitemid 38233585)
100. Stumvoll M, Haring H. Resistin and adiponectin of mice and men. Obes Res 2002; 10: 1197-1199.
101. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res 2003; 11: 997-1001. (Pubitemid 41137512)
102. Bouchard L, Weisnagel SJ, Engert JC, Hudson TJ, Bouchard C, Vohl MC, et al. Human resistin gene polymorphism is associated with visceral obesity and fasting and oral glucose stimulated C-peptide in the Quebec Family Study. J Endocrinol Invest 2002; 27: 1003-1009.
103. McTernan PG, McTernan CL, Chetty R, Jenner K, Fisher FM, Lauer MN, et al. Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 2002; 87: 2407-2410. (Pubitemid 34521539)
104. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003; 88: 4848-4856 (Pubitemid 37357535)
105. Kusminski CM, da Silva NF, Creely SJ, Fisher FM, Harte AL, Baker AR, et al. The in vitro effects of resistin on the innate immune signaling pathway in isolated human subcutaneous adipocytes. J Clin Endocrinol Metab 2007; 92: 270-276.
106. Janowska J, Zahorska-Markiewicz B, Olszanecka-Glinianowicz M. Relationship between serum resistin concentration and proinflammatory cytokines in obese women with impaired and normal glucose tolerance. Metabolism 2006; 55: 1495-1499. (Pubitemid 44537347)
107. Kunnari A, Ukkola O, Päivänsalo M, Kesäniemi YA. High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. J Clin Endocrinol Metab 2006; 91: 2755-2760. (Pubitemid 44024647)
108. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111: 932-939. (Pubitemid 40279897)
109. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule ob selectively impair insulin action on glucose production. J Clin Invest 2003; 111: 225-230. (Pubitemid 36105921)
110. Bo S, Gambino R, Pagani A, Guidi S, Gentile L, Cassader M, et al. Relationships between human serum resistin, inflammatory markers and insulin resistance. Int J Obes (Lond) 2005; 29(11): 1315-1320. (Pubitemid 41679262)
111. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin mRNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003; 309: 286-290. (Pubitemid 37025889)
112. Winkler G, Kiss S, Keszthelyi L, Sápi Z, Ory I, Salamon F, et al. Expression of tumor necrosis factor α (TNFα) protein in the subcutaneous and visceral adipose tissue in correlation with adipocyte cell volume, serum TNFa soluble serum receptor-2 concentrations and C-peptide level. Eur J Endocrinol 2003; 149: 129-135. (Pubitemid 36987155)
113. Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004; 1: e45. (Pubitemid 40412718)
114. Vendrell J, Broch M, Vilarrasa N, Molina A, Gómez JM, Gutiérrez C, et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationship in obesity. Obes Res 2004; 12: 962-971 (Pubitemid 41202398)
115. Stejskal D, Adamovská S, Bartek J, Juráková R, Prosková J. Resistin concentrations in persons with type 2 diabetes mellitus and in individuals with acute inflammatory disease. Biomed Papers 2003; 147: 63-69.
116. Janowska . J, Zahorska-Markiewicz B., Olszanecka-Glinianowicz M.Relationship between serum resistin concentration and proinflammatory cytokines in obese women with impaired and normal glucose tolerance. Metabolism 2008; 55: 1495-1499.
117. Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001; 285: 561-562. (Pubitemid 32918109)
118. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004; 27: 2245-2450. (Pubitemid 39281400)
119. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312. (Pubitemid 32151228)
120. Muse ED, Obici S, Bhanot S, Monia BP, McKay RA, Rajala MW, et al. Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest 2004; 114: 232-239. (Pubitemid 39071628)
121. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430. (Pubitemid 40139988)
122. López-Bermejo A, Chico-Julià B, Fernàndez-Balsells M, Recasens M, Esteve E, Casamitjana R, et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006; 55: 2871-2875. (Pubitemid 44923689)
123. Curat CA, Wegner V, Sengenès C, Miranville A, Tonus C, Busse R, et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006; 49: 744-777. (Pubitemid 43357549)
124. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994; 14: 1431-1437. (Pubitemid 24984261)
125. Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, et al. Pre- B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004; 113: 1318-1327. (Pubitemid 39069931)
126. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748-1758 (Pubitemid 46154646)
127. Ye S, Simon B, Maloney J, Zambelli-Weiner A, Gao L, Grant A, et al. Pre-B-cell colony-enhancing factor as a potential Novel biomarker in acute lung injury. Am J Respir Crit Care Med 2005; 171: 361-370. (Pubitemid 40223404)
128. Dahl TB, Yndestad A, Skjelland M, Øie E, Dahl A, Michelsen A, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007; 115: 972-980. (Pubitemid 46328290)